SiBone (NASDAQ:SIBN - Get Free Report) SVP Michael Pisetsky sold 3,725 shares of SiBone stock in a transaction on Monday, August 17th. The shares were sold at an average price of $18.63, for a total value of $69,396.75. Following the completion of the transaction, the senior vice president owned 273,650 shares of the company's stock, valued at approximately $5,098,099.50. This trade represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
SiBone Trading Up 2.4%
Shares of SIBN stock opened at $19.14 on Wednesday. The company has a market capitalization of $848.86 million, a PE ratio of -56.29 and a beta of 0.66. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89. The business's fifty day moving average is $17.22 and its 200 day moving average is $15.25. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15.
SiBone (NASDAQ:SIBN - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The business had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. On average, equities research analysts anticipate that SiBone will post -0.4 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. First Light Asset Management LLC raised its holdings in SiBone by 6.4% in the 1st quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company's stock worth $67,611,000 after purchasing an additional 320,286 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of SiBone by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company's stock valued at $49,331,000 after purchasing an additional 11,566 shares in the last quarter. Granahan Investment Management LLC increased its position in shares of SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock valued at $21,965,000 after buying an additional 858,942 shares during the period. Nuveen LLC increased its position in shares of SiBone by 5.1% during the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company's stock valued at $28,041,000 after buying an additional 69,229 shares during the period. Finally, Impax Asset Management Group plc raised its stake in SiBone by 17.1% in the fourth quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company's stock worth $23,664,000 after buying an additional 175,000 shares in the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
SIBN has been the subject of a number of recent research reports. TD Cowen boosted their target price on SiBone from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Truist Financial reaffirmed a "buy" rating and issued a $23.00 price target (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Weiss Ratings downgraded SiBone from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, August 5th. Finally, UBS Group increased their price objective on SiBone from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, SiBone currently has an average rating of "Moderate Buy" and a consensus target price of $24.17.
Read Our Latest Analysis on SiBone
SiBone Company Profile
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
